Mitral valve and heart muscle study for people taking mavacamten
Part of Heart & circulation clinical trials.
This study looks at how problems with the mitral valve (the door between two heart chambers) affect people with a type of heart muscle disease called hypertrophic cardiomyopathy. If you are already taking a medicine called mavacamten and have symptoms like shortness of breath, this registry may help doctors understand your condition better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years old or older.
- Have obstructive hypertrophic cardiomyopathy (a condition where the heart muscle is thickened and blocks blood flow).
- Have symptoms like breathlessness or chest pain that limit daily activities (NYHA class 2 or 3).
- Have a significant blockage in the heart, with a pressure gradient of at least 50 mmHg (measured at rest or during a special breathing check).
- Already be taking mavacamten (a medicine that relaxes the heart muscle).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether mavacamten, a medication that may help the heart use energy better, can improve symptoms in people with obstructive hypertrophic cardiomyopathy. It aims to see if this drug helps with chest pain and shortness of breath, and improve overall heart function.
This study tests whether the drug mavacamten (Camzyos) improves blood flow in the heart's small vessels for people with obstructive hypertrophic cardiomyopathy. You will take mavacamten as prescribed and have a PET/CT scan to measure your heart's blood flow reserve.
This study looks at adults with a heart condition called obstructive hypertrophic cardiomyopathy. It tracks what happens after they start taking the medicine mavacamten, to learn more about its effects and how it works in real life.
This study collects real-world information about people with obstructive hypertrophic cardiomyopathy (HCM) who are being treated with mavacamten or other standard medicines. It aims to understand patient characteristics, treatment choices over time, and long-term outcomes.
This study looks at how mavacamten (a heart medication) works for people with obstructive hypertrophic cardiomyopathy (HCM)—a condition where heart muscle becomes too thick. Researchers will review medical records and ask patients about their experiences with the treatment.
This study looks at how well mavacamten works in real life for adults with obstructive hypertrophic cardiomyopathy, a condition where the heart muscle is thickened and blocks blood flow. It may help improve symptoms like shortness of breath or chest pain.
Hear when a new Cardiomyopathy, Hypertrophic Obstructive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.